GREATER MANCHESTER, UK – Carocell Bio, the UK- and US-based company focused on the development of anti-inflammatory therapeutics, announced that today, Thursday, 24 February 2022, its CEO Dr Mike Davies, will present at Rocket Pitch + Power Networking, a CONNECTpreneur Investor Network Virtual Event, between 4-6 pm GMT. Described as one of the world’s largest investor pitch events, and attracting a substantial ‘mid-Atlantic’ audience, the meeting will host a variety of business leaders, early-stage entrepreneurs, and investors such as Blackstone and Google Ventures. In his pitch, Dr Davies will present Carocell Bio including details of its proprietary peptide-based therapeutic pipeline to prevent the formation of a scar after an operation.
Inflammation contributes to pain and scarring with after surgery. Carocell Bio is focused on reducing this inflammation by targeting the intracellular inflammatory cascade with its proprietary peptides, in combination with advanced nanoparticle technology. The company’s pre-clinical studies have demonstrated that its lead peptide, JEL3108, offers approximately greater selectivity for a key component of the inflammatory cascade, p38-alpha (mitogen-activated protein kinase, MAPK). This indicates significant potential for the peptide technology to deliver a safe and targeted therapy.
In November 2021 the company announced additional funding of £150,000 from Deepbridge Capital. Earlier this month, Mike also spoke at the 2022 BIO CEO and Investor Conference in New York, USA.